CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-239

Not much movement in sight sciences results.
- down 9% on PCP
- up 11% on least qtr

interesting bits are
1) summary of proposed fees changes which will benefit us also
2) they have a 5% increase in ordering accounts and talk about growth in the sector overall, which given their existing large base of glaucoma surgeons could indicate move cataract surgeons moving to combined surgery which is a trend that would also benefit us

their current qtrly revenue is so large compared to us it’s not yet possible to see what’s qtrly fluctuations versus market share erosions due to our superior device. This will become muchmore obvious in the next 6/12/18 months

https://investors.sightsciences.com/news-releases/news-release-details/sight-sciences-reports-second-quarter-2024-financial-results-and